XYXinya Yuan

Xinya Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinya Yuan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Guangyuan Hu

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    2 shared publications
  • Bi Peng

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Guo-Xian Long

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Jianing Zhang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Qiang Zhang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    1 shared publication
  • Taohua Chen

    Department of Clinical Medicine, The Second Clinical College of Guangzhou Medical University, Guangzhou 511436, China

    1 shared publication

Latest Publications

  • Open Access

    Research Progress and Challenges in Targeting GLUT1 in Tumors

    by Taohua Chen, Bi Peng, Xinya Yuan, Yizhou Liu, Jianing Zhang, Yizhen Su, Guangyuan Hu, Zhen Tao, Guoxian Long

    The solute carrier family 2 member 1 (SLC2A1), which encodes glucose transporter 1 (GLUT1), has long been recognized as a key driver of aerobic glycolysis in cancer. However, accumulating evidence has substantially expanded this view, revealing that GLUT1 functions not only as a critical mediator of metabolic reprogramming but also as an important regulator linking tumor metabolism to immune evasion. Notably, GLUT1 expression, regulation, and functional dependence are highly context-dependent across tumor types, disease states, and cellular compartments. Recent studies further link GLUT1-dependent glycolytic flux to immune regulation through glucose competition, lactate accumulation, and metabolite-dependent epigenetic programs within the tumor microenvironment. Reflecting this evolving understanding, therapeutic strategies targeting GLUT1 have progressed from simple metabolic inhibition to approaches that exploit tumor-specific metabolic dependencies and extend to regulated cell death, combination therapy, precision delivery, and selective modulation of malignant and non-malignant cellular compartments. These advances support a shift from expression-centered targeting toward strategies guided by functional GLUT1 dependence and cellular context, while recognizing the metabolic and physiological constraints that shape the therapeutic window. In this review, we systematically summarize recent advances in GLUT1 expression heterogeneity, multilayered regulatory networks, metabolic–immune crosstalk, diagnostic and prognostic relevance, and therapeutic targeting, and discuss how these insights may refine biomarker development, patient selection, and the clinical translation of GLUT1-directed precision metabolic therapy.

  • Top Cited Papers
    Open Access

    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges

    by Qiang Zhang, Wan Zhang, Xinya Yuan, Xiaohong Peng, Guangyuan Hu

    With the global trend of population aging becoming increasingly pronounced, the incidence of central nervous system (CNS) disorders continues to rise, posing a significant challenge to public health systems worldwide. Currently, many CNS disorders lack effective treatments, prompting researchers to investigate the therapeutic potential of natural compounds. Urolithin A (UA), a gut microbiota-derived metabolite of ellagitannins and ellagic acid, can cross the blood–brain barrier and exhibits a favorable safety profile. This review summarizes the biosynthesis, pharmacokinetic profile, and key biological effects of UA, including its promotion of mitophagy and mitochondrial homeostasis, as well as its anti-inflammatory, antioxidant, anti-senescence, and anti-apoptotic properties. We comprehensively summarize the preclinical evidence demonstrating UA’s therapeutic potential in CNS disorders, such as Alzheimer’s disease, Parkinson’s disease, and stroke. Recent clinical trials involving UA are presented, followed by a thorough analysis of the challenges associated with translating UA-based interventions into clinical practice for CNS disorders. This work aims to support the development of UA-based therapies to improve patient outcomes and address the growing global burden of CNS disorders.